NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.
The Berg platform is used to compare and study normal and disease signatures by integrating a range of data sets, including genomic, metabolomic, proteomic, and lipidomic data. Under the partnership, Berg Pharma will have access to clinically annotated tissue samples representing various types of Parkinson's disease and specific mutations.
Parkinson's Institute Founder, Scientific Director, and CEO William Langston said in a statement that applying the Berg platform with the institute's resources and knowledge may help speed up the hunt for causes and treatments for the disease.
Cambridge, Mass.-based Berg Pharma has a pipeline of early-stage technologies used in developing biomarkers and therapeutics for central nervous system and metabolic diseases.
Financial terms of the agreement were not released.